Alivus Life Sciences Announces Unaudited Financial Results for Q1 Ended June 30, 2025
The financial results provide insight into the company's performance, which is relevant to investors and stakeholders.
The announcement primarily focuses on the positive financial results for Q1 2025, indicating a stable financial performance.
* Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) approved the unaudited financial results for the first quarter ended June 30, 2025. * Total Income for the quarter stood at ₹6,108.31 Million. * Profit before tax was ₹1,629.81 Million. * Total tax expenses were ₹414.46 Million. * Profit for the period was ₹1,215.35 Million. * Basic earnings per share was ₹9.91. * The results have been subjected to Limited Review by Walker Chandiok & Co. LLP, the Statutory Auditor of the company, who have expressed an unmodified conclusion on the said results.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.